Literature DB >> 17353346

Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.

Cary Hsu1, Stephanie A Jones, Cyrille J Cohen, Zhili Zheng, Keith Kerstann, Juhua Zhou, Paul F Robbins, Peter D Peng, Xinglei Shen, Theotonius J Gomes, Cynthia E Dunbar, David J Munroe, Claudia Stewart, Kenneth Cornetta, Danny Wangsa, Thomas Ried, Steven A Rosenberg, Richard A Morgan.   

Abstract

Malignancies arising from retrovirally transduced hematopoietic stem cells have been reported in animal models and human gene therapy trials. Whether mature lymphocytes are susceptible to insertional mutagenesis is unknown. We have characterized a primary human CD8(+) T-cell clone, which exhibited logarithmic ex vivo growth in the absence of exogenous cytokine support for more than 1 year after transduction with a murine leukemia virus-based vector encoding the T-cell growth factor IL-15. Phenotypically, the clone was CD28(-), CD45RA(-), CD45RO(+), and CD62L(-), a profile consistent with effector memory T lymphocytes. After gene transfer with tumor-antigen-specific T-cell receptors, the clone secreted IFN-gamma upon encountering tumor targets, providing further evidence that they derived from mature lymphocytes. Gene-expression analyses revealed no evidence of insertional activation of genes flanking the retroviral insertion sites. The clone exhibited constitutive telomerase activity, and the presence of autocrine loop was suggested by impaired cell proliferation following knockdown of IL-15R alpha expression. The generation of this cell line suggests that nonphysiologic expression of IL-15 can result in the long-term in vitro growth of mature human T lymphocytes. The cytokine-independent growth of this line was a rare event that has not been observed in other IL-15 vector transduction experiments or with any other integrating vector system. It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353346      PMCID: PMC1890824          DOI: 10.1182/blood-2006-06-029173

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Murine leukemia induced by retroviral gene marking.

Authors:  Zhixiong Li; Jochen Düllmann; Bernd Schiedlmeier; Manfred Schmidt; Christof von Kalle; Johann Meyer; Martin Forster; Carol Stocking; Anke Wahlers; Oliver Frank; Wolfram Ostertag; Klaus Kühlcke; Hans-Georg Eckert; Boris Fehse; Christopher Baum
Journal:  Science       Date:  2002-04-19       Impact factor: 47.728

Review 2.  Focus on acute leukemias.

Authors:  D Gary Gilliland; Martin S Tallman
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

3.  Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.

Authors:  K Liu; S A Rosenberg
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth.

Authors:  C E Dunbar; T M Browder; J S Abrams; A W Nienhuis
Journal:  Science       Date:  1989-09-29       Impact factor: 47.728

5.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

6.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.

Authors:  N J Caplen; S Parrish; F Imani; A Fire; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.

Authors:  Stephanie Laufs; K Zsuzsanna Nagy; Frank A Giordano; Agnes Hotz-Wagenblatt; W Jens Zeller; Stefan Fruehauf
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

8.  Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.

Authors:  D Eaton; D E Gilham; A O'Neill; R E Hawkins
Journal:  Gene Ther       Date:  2002-04       Impact factor: 5.250

9.  Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.

Authors:  Hideki Hanawa; Peiman Hematti; Keyvan Keyvanfar; Mark E Metzger; Allen Krouse; Robert E Donahue; Steve Kepes; John Gray; Cynthia E Dunbar; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

10.  Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.

Authors:  Rick S Mitchell; Brett F Beitzel; Astrid R W Schroder; Paul Shinn; Huaming Chen; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Biol       Date:  2004-08-17       Impact factor: 8.029

View more
  51 in total

1.  Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase.

Authors:  Eugene V Barsov
Journal:  Curr Protoc Immunol       Date:  2011-11

Review 2.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

3.  Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Authors:  Sebastian Newrzela; Kerstin Cornils; Tim Heinrich; Julia Schläger; Ji-Hee Yi; Olga Lysenko; Janine Kimpel; Boris Fehse; Dorothee von Laer
Journal:  Mol Med       Date:  2011-07-27       Impact factor: 6.354

Review 4.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

Review 5.  Development of CAR T cells designed to improve antitumor efficacy and safety.

Authors:  Janneke E Jaspers; Renier J Brentjens
Journal:  Pharmacol Ther       Date:  2017-03-22       Impact factor: 12.310

Review 6.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

7.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

8.  Network model of survival signaling in large granular lymphocyte leukemia.

Authors:  Ranran Zhang; Mithun Vinod Shah; Jun Yang; Susan B Nyland; Xin Liu; Jong K Yun; Réka Albert; Thomas P Loughran
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

9.  Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).

Authors:  Sung Hee Yoon; Jin Myung Lee; Sun-Je Woo; Min-Ji Park; Jung-Sun Park; Hye-Sung Kim; Mi-Young Park; Hyun-Jung Sohn; Tai-Gyu Kim
Journal:  J Clin Immunol       Date:  2009-06-11       Impact factor: 8.317

10.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.